VIDEO: Avacincaptad pegol for geographic atrophy shows positive efficacy data at 2 years
Click Here to Manage Email Alerts
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, discusses 2-year expanded efficacy data on avacincaptad pegol, or ACP, for geographic atrophy.
He also presented an analysis comparing ACP and pegcetacoplan at 12 months.
“This analysis shows us that we have seen, in this matched, indirect comparison, better efficacy of ACP compared to pegcetacoplan, and in terms of visual acuity, we are seeing a benefit in patients at month 12 that were treated with ACP compared to pegcetacoplan,” Khanani said.
Collapse
Khanani AM. 2-year expanded efficacy data from the GATHER 2 trial. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).
Read more about
Click Here to Manage Email Alerts